WO2005023291A3 - Use of glp1-agonists in the treatment of patients with type i diabetes - Google Patents

Use of glp1-agonists in the treatment of patients with type i diabetes Download PDF

Info

Publication number
WO2005023291A3
WO2005023291A3 PCT/DK2004/000599 DK2004000599W WO2005023291A3 WO 2005023291 A3 WO2005023291 A3 WO 2005023291A3 DK 2004000599 W DK2004000599 W DK 2004000599W WO 2005023291 A3 WO2005023291 A3 WO 2005023291A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
type
patients
treatment
glp
Prior art date
Application number
PCT/DK2004/000599
Other languages
French (fr)
Other versions
WO2005023291A2 (en
Inventor
Lars Hansen
Henrik Bindesboel Mortensen
Original Assignee
Novo Nordisk As
Koebenhavns Amt
Lars Hansen
Henrik Bindesboel Mortensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Koebenhavns Amt, Lars Hansen, Henrik Bindesboel Mortensen filed Critical Novo Nordisk As
Publication of WO2005023291A2 publication Critical patent/WO2005023291A2/en
Publication of WO2005023291A3 publication Critical patent/WO2005023291A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Abstract

The present invention relates to the use of GLP-1 agonists in the treatment of patients with type I diabetes, where the patient is newly diagnosed with type 1 diabetes when treatment with the GLP-1 agonist is initiated. The present invention also relates to the use of GLP-1 agonists to prolong the remission period in such patients. The present invention further re-lates to a diagnostic test which utilizes measurement of endogenous GLP-1 levels to predict loss of beta cell function in patients with type I diabetes. The present invention further relates to methods for determining whether a patient with type 1 diabetes is in need of treatment with a GLP-1 agonist and/or is in remission.
PCT/DK2004/000599 2003-09-11 2004-09-10 Use of glp1-agonists in the treatment of patients with type i diabetes WO2005023291A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301321 2003-09-11
DKPA200301321 2003-09-11
US50550003P 2003-09-24 2003-09-24
US60/505,500 2003-09-24

Publications (2)

Publication Number Publication Date
WO2005023291A2 WO2005023291A2 (en) 2005-03-17
WO2005023291A3 true WO2005023291A3 (en) 2005-04-28

Family

ID=34276709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000599 WO2005023291A2 (en) 2003-09-11 2004-09-10 Use of glp1-agonists in the treatment of patients with type i diabetes

Country Status (1)

Country Link
WO (1) WO2005023291A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8658174B2 (en) 2005-07-27 2014-02-25 Qinghua Wang GLP/1/exendin 4 IgG Fc fusion constructs for treatment of diabetes
CA2649932A1 (en) * 2006-05-02 2007-11-15 Actogenix Nv Microbial intestinal delivery of obesity related peptides
NZ592283A (en) 2008-10-17 2012-09-28 Sanofi Aventis Deutschland Combination of an insulin and the GLP-1 agonist AVE0010
MX2012005184A (en) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine.
MX2012005186A (en) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine.
JP6199186B2 (en) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
ES2610362T3 (en) 2011-01-25 2017-04-27 Viviabiotech, S.L. 1,2,4-Oxadiazole derivatives as receptor modulating drugs for the glp-1 peptide
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US10105442B2 (en) 2014-05-07 2018-10-23 Novo Nordisk A/S Treatment of diabetes type 1 using GLP-1 and anti-IL-21
JP6970615B2 (en) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin glargine / lixisenatide fixed ratio prescription
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
WO2019200594A1 (en) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Acylated glp-1 derivative
BR112021021976A2 (en) * 2019-05-02 2022-01-11 Closed Loop Medicine Ltd Methods and systems for delivering personalized medicine to a patient

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201187A1 (en) * 1985-03-29 1986-11-12 Novo Nordisk A/S Determination of glycated (glycosylated) hemoglobin in blood
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201187A1 (en) * 1985-03-29 1986-11-12 Novo Nordisk A/S Determination of glycated (glycosylated) hemoglobin in blood
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DANNE T ET AL: "Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group.", DIABETES CARE. AUG 2001, vol. 24, no. 8, August 2001 (2001-08-01), pages 1342 - 1347, XP002319817, ISSN: 0149-5992 *
HOEY H ET AL: "Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes.", DIABETES CARE. NOV 2001, vol. 24, no. 11, November 2001 (2001-11-01), pages 1923 - 1928, XP002319818, ISSN: 0149-5992 *
NORDLY S ET AL: "Quality of diabetes management in children and adolescents in Denmark.", DIABETIC MEDICINE : A JOURNAL OF THE BRITISH DIABETIC ASSOCIATION. JUL 2003, vol. 20, no. 7, July 2003 (2003-07-01), pages 568 - 574, XP002319819, ISSN: 0742-3071 *
OLSEN BIRTHE SUSSANE ET AL: "A 6-year nationwide cohort study of glycaemic control in young people with Type 1 diabetes: Risk markers for the development of retinopathy, nephropathy, and neuropathy", JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol. 14, no. 6, November 2000 (2000-11-01), pages 295 - 300, XP002319816, ISSN: 1056-8727 *
VILSBOELL T ET AL: "EVALUATION OF BETA-CELL SECRETORY CAPACITY USING GLUCAGON-LIKE PEPTIDE 1", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 23, no. 6, June 2000 (2000-06-01), pages 807 - 812, XP000984497, ISSN: 0149-5992 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Also Published As

Publication number Publication date
WO2005023291A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2005023291A3 (en) Use of glp1-agonists in the treatment of patients with type i diabetes
Blüher et al. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes
Brydon et al. Stress-induced increases in interleukin-6 and fibrinogen predict ambulatory blood pressure at 3-year follow-up
Kwong et al. Imprecision of urinary iothalamate clearance as a gold-standard measure of GFR decreases the diagnostic accuracy of kidney function estimating equations
Kuwa et al. Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma
EP3712279B1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
Hjelmesæth et al. Insulin resistance after renal transplantation: impact of immunosuppressive and antihypertensive therapy
Burkhardt et al. Creatinine clearance, Cockcroft-Gault formula and cystatin C: estimators of true glomerular filtration rate in the elderly?
Vitellaro‐Zuccarello et al. Stereological analysis of collagen and elastic fibers in the normal human dermis: variability with age, sex, and body region
EP2113774A3 (en) PIGF and Flt-1 as prognostic parameters for cardiovascular illnesses
TW200600060A (en) Apparatus for the manufacture of medical devices
SE9401351D0 (en) A method of diagnosis
WO2008005814A3 (en) Method and apparatus for diagnosing pre-eclampsia
Michel et al. Urinary angiotensinogen excretion is associated with blood pressure independent of the circulating renin–angiotensin system in a group of African ancestry
Yılmaz Agladioglu et al. Urinary C-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: a single-center experience
WO2006116688A3 (en) Mif agonists and antagonists and therapeutic uses thereof
EP1162461A3 (en) Automated method for detecting, quantifying and monitoring exogenous hemoglobin in whole blood, plasma and serum
Olson et al. Noninvasive skin fluorescence spectroscopy is comparable to hemoglobin A1c and fasting plasma glucose for detection of abnormal glucose tolerance
ATE479707T1 (en) DIAGNOSIS AND RECORDING OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SCLERODERM
Palatini et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension
WO2005079410A3 (en) Biological profiles and methods of use
Arrendale et al. Assessment of glycated hemoglobin using A1CNow™ point-of-care device as compared to central laboratory testing
Yamada et al. Evaluation of the relationship between glycated hemoglobin A1c and mean glucose levels derived from the professional continuous flash glucose monitoring system
NZ540750A (en) Sets of oligonucleotide probes for diagnosis
Graci et al. The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase